Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response
Therapeutic Advances in Psychopharmacology
Published online on March 27, 2026
Abstract
Therapeutic Advances in Psychopharmacology, Volume 16, January-December 2026.
Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia. Despite ...
Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia. Despite ...